CNS Clinical Trials and Brain Metastases
Registration Now Open

Registration for the 2nd Annual Conference on CNS Clinical Trials and Brain Metastases is now open. SNO and ASCO members receive discounted registration rates. Online registration closes on Friday, August 5, 2022. On-site registration will be available with a $50 surcharge.

Registration for the conference includes access to the following:
- Scientific and Independent Supported Sessions
- A special Town Hall
- Breakfast, lunch, and refreshment breaks
- Poster reception at the Sheraton Centre Toronto Hotel
- Networking reception with Meet the Exhibitors in the Exhibit Hall
- Recorded content following the conference
- Poster e-Gallery

To view the program and to register click here.

From The Journals

From Neuro-Oncology Practice
Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians
The Central Brain Tumor Registry of the United States (CBTRUS) contains information on all primary brain and other central nervous system (CNS) tumors diagnosed in the United States (US). Here we summarize the 2021 CBTRUS annual statistical report for clinicians. Click here to read the full article.

Upcoming Webinars
The Society for Neuro-Oncology's Molecular Pathology Special Interest Track is pleased to announce the quarterly event for the SNO Pathology FAST (First Author Series Talk) webinar series. The webinar entitled Spatial Immunogenomic Heterogeneity of Malignant Brain Tumors will occur live on Monday May 16, 2022, at 1:00pm - 2:00pm EDT. Click here to register.

The Pediatric Special Interest Track is pleased to present the next broadcast of the Pediatric Tumor Board Series. The broadcast entitled Posterior fossa ependymoma: Current upfront and relapse management strategies in the molecular era will occur live on May 24, 2022, 12:30-2:00 pm EDT. Click here to register.

Featured Clinical Trial

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32) Building on EF-14, the TRIDENT (EF-32) trial is an international open-label randomized study of Optune (Tumor Treating Fields or TTF) concomitant with radiation and temozolomide versus adjuvant TTF in patients with newly diagnosed glioblastoma. Read more here.

SNO Career Center

This Week's Featured Listing
Miami Cancer Institute (MCI), Baptist Health South Florida (BHSF) is looking to hire a full-time neuro-oncologist to a multidisciplinary, academic/hybrid CNS tumor program, including a neuro-oncology director, chair of medical oncology, 4 neurosurgeons and 4 CNS radiation oncologists. Click here to apply or see other postings!

Upcoming SNO and SNO Affiliated Events

2022 SNO Annual Meeting and Education Day - Call for Abstracts
Abstract deadline - June 1, 2022
This deadline will not be extended. For information on the submission categories and requirements, please click here.

The 20th International Symposium of Pediatric Neuro-Oncology (ISPNO 2022)
June 12-15, 2022, in Hamburg
Register Here
For information about travel grants for LMIC countries, please click here.
Sponsorship Opportunities

If you are interested in exhibiting or sponsoring at one of our upcoming events, please contact partnerships@soc-neuro-onc.org for your customized package today. To view the prospectus for the 2nd Annual Conference on Clinical Trials and Brain Metastases, click here. To view the prospectus for the 2022 SNO Annual Meeting and Education Day, click here. If you are interested in hosting an investigator meeting or social event concurrently during our annual meeting, please contact gabrielle@soc-neuro-onc.org

SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at snodigest@soc-neuro-onc.org.